tetano
Editor, Senior Moderator
Vaccine. 2016 Jul 26. pii: S0264-410X(16)30591-6. doi: 10.1016/j.vaccine.2016.07.018. [Epub ahead of print]
[h=1]High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.[/h] Kim JH[SUP]1[/SUP], Talbot HK[SUP]2[/SUP], Mishina M[SUP]3[/SUP], Zhu Y[SUP]4[/SUP], Chen J[SUP]1[/SUP], Cao W[SUP]1[/SUP], Reber AJ[SUP]1[/SUP], Griffin MR[SUP]4[/SUP], Shay DK[SUP]1[/SUP], Spencer SM[SUP]1[/SUP], Sambhara S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] High-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals ⩾65years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n=12-26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine-specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults.
[h=4]TRIAL REGISTRATION:[/h] ClinicalTrials.gov NCT 01189123.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Cell-mediated immunity; High-dose influenza vaccine; Older adults; Plasmablast response
PMID: 27473306 DOI: 10.1016/j.vaccine.2016.07.018
[PubMed - as supplied by publisher]
[h=1]High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.[/h] Kim JH[SUP]1[/SUP], Talbot HK[SUP]2[/SUP], Mishina M[SUP]3[/SUP], Zhu Y[SUP]4[/SUP], Chen J[SUP]1[/SUP], Cao W[SUP]1[/SUP], Reber AJ[SUP]1[/SUP], Griffin MR[SUP]4[/SUP], Shay DK[SUP]1[/SUP], Spencer SM[SUP]1[/SUP], Sambhara S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] High-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals ⩾65years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n=12-26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine-specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults.
[h=4]TRIAL REGISTRATION:[/h] ClinicalTrials.gov NCT 01189123.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Cell-mediated immunity; High-dose influenza vaccine; Older adults; Plasmablast response
PMID: 27473306 DOI: 10.1016/j.vaccine.2016.07.018
[PubMed - as supplied by publisher]